TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2006028480A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Clonex Development, Inc. |
Cell lines for use in increasing protein yield form a cell culture
|
WO2006129828A2
(en)
|
2005-05-31 |
2006-12-07 |
Canon Kabushiki Kaisha |
Target substance capturing molecule
|
JP5322653B2
(en)
|
2005-11-28 |
2013-10-23 |
ザイモジェネティクス, インコーポレイテッド |
IL-21 antagonist
|
AU2015203464B2
(en)
*
|
2006-02-13 |
2017-08-10 |
Monsanto Technology Llc |
Plant chimeric binding polypeptides for universal molecular recognition
|
AR059448A1
(en)
|
2006-02-13 |
2008-04-09 |
Divergence Inc |
UNION VEGETABLE CHEMICAL POLIPEPTIDES FOR UNIVERSAL MOLECULAR RECOGNITION
|
AU2013201171B2
(en)
*
|
2006-02-13 |
2016-01-21 |
Monsanto Technology Llc |
Plant chimeric binding polypeptides for universal molecular recognition
|
US7897568B2
(en)
|
2006-03-03 |
2011-03-01 |
Vinay K. Singh |
Compositions for treatment of cancer
|
MX2008013705A
(en)
|
2006-04-28 |
2008-11-06 |
Esbatech Ag |
Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk.
|
EA200970250A1
(en)
|
2006-09-05 |
2010-02-26 |
Медарекс, Инк. |
ANTIBODIES TO BONE MORPHOGENETIC PROTEINS AND THEIR RECEPTORS AND METHODS OF THEIR APPLICATION
|
KR20150065959A
(en)
|
2006-10-02 |
2015-06-15 |
메다렉스, 엘.엘.시. |
Human antibodies that bind cxcr4 and uses thereof
|
JP5207222B2
(en)
*
|
2006-11-17 |
2013-06-12 |
独立行政法人農業生物資源研究所 |
Protein production method using repetitive sequence such as leucine rich repeat (LRR) sequence
|
MX2009005466A
(en)
|
2006-11-22 |
2009-08-17 |
Adnexus A Bristol Myers Sqibb |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir.
|
KR101552735B1
(en)
|
2006-12-01 |
2015-09-14 |
메다렉스, 엘.엘.시. |
22 human antibodies that bind cd22 and uses thereof
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
EP2097534A4
(en)
|
2006-12-14 |
2010-05-12 |
Medarex Inc |
Human antibodies that bind cd70 and uses thereof
|
EP3202786A3
(en)
|
2007-03-12 |
2017-10-11 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequence based engineering and optimization of single chain antibodies
|
CA2682350A1
(en)
*
|
2007-04-11 |
2008-10-23 |
The Jackson Laboratory |
Diagnosis and treatment of diseases caused by misfolded proteins
|
DK2208737T3
(en)
|
2007-05-03 |
2017-09-18 |
Lysomab Gmbh |
Complement factor H-derived short-consensus repeat antibody constructs
|
BRPI0812400A2
(en)
|
2007-06-05 |
2014-10-29 |
Univ Yale |
UNIT, HYBRIDOMA, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING A UNIT, ANTIBODY ISOLATED TO A SAME ANTIGEN CONNECTION UNIT, PEPTIDES MOLECULE, AND UNIT USE.
|
ES2532725T3
(en)
|
2007-06-25 |
2015-03-31 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Genetic engineering modification based on sequence and optimization of single chain antibodies
|
MX2009013328A
(en)
|
2007-06-25 |
2010-06-02 |
Esbatech An Alcon Biomedical R |
Methods of modifying antibodies, and modified antibodies with improved functional properties.
|
EP2198022B1
(en)
*
|
2007-09-24 |
2024-03-06 |
University Of Zurich |
Designed armadillo repeat proteins
|
EA023031B1
(en)
|
2007-11-30 |
2016-04-29 |
Глаксо Груп Лимитед |
Antigen-binding construct and use thereof
|
AU2008364115B2
(en)
|
2007-12-07 |
2013-11-21 |
Zymogenetics, Inc. |
Anti-human IL-21 monoclonal antibodies
|
WO2009100990A1
(en)
*
|
2008-02-13 |
2009-08-20 |
Dsm Ip Assets B.V. |
Process for the production of a peptide
|
MX2010008874A
(en)
|
2008-02-14 |
2010-09-22 |
Bristol Myers Squibb Co |
Targeted therapeutics based on engineered proteins that bind egfr.
|
US20110262964A1
(en)
*
|
2008-03-19 |
2011-10-27 |
Hugues Bedouelle |
Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
|
EP2103936A1
(en)
*
|
2008-03-19 |
2009-09-23 |
Institut Pasteur |
Reagentless fluorescent biosensors comprising a designed ankyrin repeat module and methods of their design and use
|
CN102056946A
(en)
|
2008-04-11 |
2011-05-11 |
中外制药株式会社 |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
UY31808A
(en)
|
2008-05-06 |
2009-12-14 |
Glaxo Group Ltd |
ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS
|
JP2011520961A
(en)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
Scaffold domain protein based on multivalent fibronectin
|
LT3241843T
(en)
|
2008-06-25 |
2021-09-27 |
Novartis Ag |
Solubility optimization of immunobinders
|
CN102177438A
(en)
|
2008-07-25 |
2011-09-07 |
理查德·W·瓦格纳 |
protein screening method
|
EP2326351B1
(en)
|
2008-08-19 |
2017-12-27 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
CN107011425B
(en)
*
|
2008-11-03 |
2021-01-01 |
分子组合公司 |
Binding proteins that inhibit VEGF-A receptor interactions
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
EP2389394A2
(en)
|
2009-01-21 |
2011-11-30 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
CA2753332A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
US20110305692A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Antigen-binding contructs
|
CN102239181A
(en)
*
|
2009-02-24 |
2011-11-09 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
Methods for identifying immunobinders of cell-surface antigens
|
WO2010097394A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
MX2011011075A
(en)
|
2009-04-20 |
2011-11-04 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17.
|
IE20090514A1
(en)
|
2009-07-06 |
2011-02-16 |
Opsona Therapeutics Ltd |
Humanised antibodies and uses therof
|
JP5426026B2
(en)
|
2009-07-28 |
2014-02-26 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Non-invasive in vivo optical imaging method
|
EP2470569A1
(en)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
EP2496605A1
(en)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
US20120282276A1
(en)
|
2009-11-05 |
2012-11-08 |
The Regents Of The University Of Michigan |
Biomarkers predictive of progression of fibrosis
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
SG182590A1
(en)
|
2010-01-28 |
2012-08-30 |
Glaxo Group Ltd |
Cd127 binding proteins
|
BR112012019902A2
(en)
|
2010-02-10 |
2019-09-24 |
Novartis Ag |
"method and compounds for muscle growth"
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
AU2011230537C1
(en)
|
2010-03-26 |
2018-08-02 |
Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
TWI667257B
(en)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
Antibodies with modified affinity to fcrn that promote antigen clearance
|
EP2563380B1
(en)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
EP2563381B1
(en)
|
2010-04-27 |
2017-08-09 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
WO2011150279A2
(en)
|
2010-05-27 |
2011-12-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
JP6008838B2
(en)
|
2010-04-29 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of asparaginyl tRNA synthetase
|
US9034320B2
(en)
|
2010-04-29 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
|
AR081361A1
(en)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
|
EP2566515B1
(en)
|
2010-05-03 |
2017-08-02 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
WO2011140132A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
CN103140233B
(en)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
|
EP2566499B1
(en)
|
2010-05-04 |
2017-01-25 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
BR112012028006A2
(en)
|
2010-05-07 |
2016-08-02 |
Hoffmann La Roche |
immunohistochemistry (ihq) method, use of a therapeutically active binding domain, kit and binding domain
|
CA3090304A1
(en)
|
2010-05-13 |
2011-11-17 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
CA2799197C
(en)
|
2010-05-14 |
2019-10-29 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
TW201210612A
(en)
|
2010-06-03 |
2012-03-16 |
Glaxo Group Ltd |
Humanised antigen binding proteins
|
EP3560962A1
(en)
|
2010-07-09 |
2019-10-30 |
Bioverativ Therapeutics Inc. |
Processable single chain molecules and polypeptides made using same
|
WO2012021247A2
(en)
|
2010-07-12 |
2012-02-16 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
SG188666A1
(en)
|
2010-09-30 |
2013-05-31 |
Agency Science Tech & Res |
Methods and reagents for detection and treatment of esophageal metaplasia
|
AR083495A1
(en)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
STABLE AND SOLUBLE ANTIBODIES
|
WO2012066058A1
(en)
|
2010-11-16 |
2012-05-24 |
Boehringer Ingelheim International Gmbh |
Agents and methods for treating diseases that correlate with bcma expression
|
TWI629355B
(en)
|
2010-11-17 |
2018-07-11 |
中外製藥股份有限公司 |
Multispecific antigen-binding molecule capable of replacing blood coagulation factor VIII
|
TR201810773T4
(en)
|
2010-11-23 |
2018-08-27 |
Glaxo Group Ltd |
Oncostatin (osm) antigen binding proteins.
|
EP2853542A1
(en)
|
2010-11-24 |
2015-04-01 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting HGF
|
RU2636552C2
(en)
|
2010-11-26 |
2017-11-23 |
Молекьюлер Партнерс Аг |
Improved n-terminal capping modules for constructed ankyrin repeat proteins
|
EP4231014A3
(en)
|
2010-11-30 |
2024-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
EP3539991A1
(en)
|
2011-01-07 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
US9499592B2
(en)
*
|
2011-01-26 |
2016-11-22 |
President And Fellows Of Harvard College |
Transcription activator-like effectors
|
CA2825919C
(en)
|
2011-02-15 |
2018-05-01 |
Immunogen, Inc. |
Methods of preparation of conjugates
|
BR112013021526B1
(en)
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
VARIANT POLYPEPTIDE, METHODS FOR MAINTAINING OR DECREASE BINDING ACTIVITIES TO FCGRIIA (TYPE R) AND FCGRIIA (TYPE H) AND INCREASING FCGRIIB BINDING ACTIVITY OF A POLYPEPTIDE AND FOR SUPPRESSING THE PRODUCTION OF AN ANTIBODY AGAINST A POLYENDENDOPEPTIDE ANTIBODY FC, METHODS FOR THE PRODUCTION OF SUCH POLYPEPTIDE WITH MAINTAINED OR DECREASED AND INCREASED BINDING ACTIVITIES AND FOR THE SUPPRESSED PRODUCTION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF A POLYPEPTIDE
|
EP3825325A3
(en)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
RU2016147206A
(en)
|
2011-04-15 |
2018-10-19 |
Компуджен Лтд. |
Polypeptides and polynucleotides and their use for the treatment of immunological disorders and cancer
|
BR112013027766A2
(en)
|
2011-04-29 |
2016-11-29 |
Janssen Biotech Inc |
il4 / il13 binding repeat proteins and uses
|
RU2640254C2
(en)
|
2011-05-06 |
2017-12-27 |
Нексвет Австралия Пти Лтд |
Antibodies against nerve growth factor and methods for their production and application
|
ES2905682T3
(en)
|
2011-05-06 |
2022-04-11 |
Zoetis Services Llc |
Anti-nerve growth factor antibodies and methods of preparation and use thereof
|
GB201114858D0
(en)
|
2011-08-29 |
2011-10-12 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of using the same
|
RU2640252C2
(en)
|
2011-05-06 |
2017-12-27 |
Нексвет Австралия Пти Лтд |
Antibodies against nerve growth factor and methods for their production and application
|
EA028220B1
(en)
|
2011-05-27 |
2017-10-31 |
Глаксо Груп Лимитед |
Immunoconjugate comprising bcma (cd269/tnfrsf17) binding protein, medical use thereof and pharmaceutical composition
|
DK2717898T3
(en)
|
2011-06-10 |
2019-03-25 |
Bioverativ Therapeutics Inc |
COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
|
MX343580B
(en)
|
2011-06-13 |
2016-11-10 |
Csl Ltd |
Antibodies against g-csfr and uses thereof.
|
CN103648532A
(en)
|
2011-06-21 |
2014-03-19 |
伊缪诺金公司 |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
GEP201706667B
(en)
|
2011-06-28 |
2017-05-25 |
Berlin - Chemie Ag |
Antibodies to adp-ribosyl cyclase 2
|
JP6113721B2
(en)
|
2011-06-28 |
2017-04-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Therapeutic and diagnostic targets
|
CA2839539C
(en)
|
2011-06-30 |
2021-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
AU2012317418B2
(en)
|
2011-09-30 |
2017-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
CN110680920A
(en)
|
2011-09-30 |
2020-01-14 |
中外制药株式会社 |
Antigen binding molecules that induce an immune response against a target antigen
|
TW201326209A
(en)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
IN2014CN03066A
(en)
|
2011-09-30 |
2015-08-07 |
Chugai Pharmaceutical Co Ltd |
|
EP3939996A1
(en)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
EP3617313A1
(en)
|
2011-10-05 |
2020-03-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
|
EP2771351B1
(en)
|
2011-10-28 |
2017-06-14 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
US20130156766A1
(en)
|
2011-11-15 |
2013-06-20 |
Allergan, Inc. |
Treatment of dry age related macular degeneration
|
SG10201609301QA
(en)
|
2011-11-30 |
2016-12-29 |
Chugai Pharmaceutical Co Ltd |
Drug containing carrier into cell for forming immune complex
|
EP2612916A1
(en)
|
2012-01-09 |
2013-07-10 |
Universität Zürich |
Cellular high throughput encapsulation for screening or selection
|
PL2802606T3
(en)
|
2012-01-10 |
2018-09-28 |
Biogen Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
SG11201404850SA
(en)
|
2012-02-13 |
2014-09-26 |
Agency Science Tech & Res |
IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
|
CA2864300A1
(en)
|
2012-02-16 |
2013-08-22 |
Atyr Pharma, Inc. |
Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
|
WO2013121038A1
(en)
|
2012-02-17 |
2013-08-22 |
Centro Nacional De Investigaciones Oncológicas |
Mammalian homologues of flower, their use in cancer diagnostics, prevention and treatment
|
DK2818183T3
(en)
|
2012-02-24 |
2020-06-15 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule to promote the disappearance of antigen by Fc RIIB
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
PL2846836T3
(en)
|
2012-05-07 |
2020-01-31 |
Allergan, Inc. |
Method of treating amd in patients refractory to anti-vegf therapy
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
WO2013180201A1
(en)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
Antigen-binding molecule for eliminating aggregated antigens
|
SG11201407963PA
(en)
|
2012-05-30 |
2015-01-29 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
JP6628966B2
(en)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
Antigen binding molecule containing an altered Fc region
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
SG11201408196RA
(en)
|
2012-06-28 |
2015-03-30 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
AR091774A1
(en)
*
|
2012-07-16 |
2015-02-25 |
Dow Agrosciences Llc |
PROCESS FOR THE DESIGN OF REPEATED, LONG, DIVERGENT DNA SEQUENCES OF OPTIMIZED CODONS
|
EP2692731A1
(en)
*
|
2012-07-31 |
2014-02-05 |
Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe |
Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EP2889376A4
(en)
|
2012-08-24 |
2016-11-02 |
Chugai Pharmaceutical Co Ltd |
MOUSE Fc RII-SPECIFIC Fc ANTIBODY
|
WO2014030728A1
(en)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
Fcγriib-specific fc region variant
|
CN105246507B
(en)
|
2012-09-07 |
2019-01-25 |
达特茅斯大学理事会 |
VISTA regulator for diagnosing and treating cancer
|
RU2683933C2
(en)
|
2012-09-28 |
2019-04-03 |
Чугаи Сейяку Кабусики Кайся |
Method for evaluating reaction of blood coagulation
|
AU2013331763B2
(en)
|
2012-10-15 |
2018-02-15 |
Universitat Zurich |
Bispecific HER2 ligands for cancer therapy
|
EP2719706A1
(en)
|
2012-10-15 |
2014-04-16 |
Universität Zürich |
Bispecific HER2 ligands for cancer therapy
|
AU2013343667A1
(en)
|
2012-11-08 |
2015-04-02 |
F. Hoffmann-La Roche Ag |
HER3 antigen binding proteins binding to the beta-hairpin of HER3
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
EP2935589A1
(en)
|
2012-12-18 |
2015-10-28 |
Novartis AG |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
KR20150122761A
(en)
|
2013-02-26 |
2015-11-02 |
로슈 글리카트 아게 |
Bispecific t cell activating antigen binding molecules
|
WO2014133855A1
(en)
|
2013-02-28 |
2014-09-04 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
EP2961435B1
(en)
|
2013-02-28 |
2019-05-01 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3566750A3
(en)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
TWI788044B
(en)
|
2013-03-15 |
2022-12-21 |
美商百歐維拉提夫治療公司 |
Factor ix polypeptide formulations
|
CN105246914B
(en)
|
2013-04-02 |
2021-08-27 |
中外制药株式会社 |
Fc region variants
|
GB201308363D0
(en)
|
2013-05-09 |
2013-06-19 |
Bagshawe Kenneth D |
Tumour therapy
|
EP3004152B1
(en)
*
|
2013-05-31 |
2020-09-30 |
Molecular Partners AG |
Designed ankyrin repeat proteins binding to hepatocyte growth factor
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR102236367B1
(en)
|
2013-07-26 |
2021-04-05 |
삼성전자주식회사 |
Bispecific chimeric proteins with DARPins
|
AU2014329437B2
(en)
|
2013-10-06 |
2018-10-18 |
F. Hoffmann-La Roche Ag |
Modified Pseudomonas exotoxin A
|
HUE047910T2
(en)
|
2013-11-05 |
2020-05-28 |
Allergan Inc |
Method of treating conditions of the eye with an anti-vegf darpin
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
CN105980557B
(en)
|
2013-12-04 |
2020-04-07 |
中外制药株式会社 |
Antigen binding molecules with variable antigen binding capacity depending on concentration of compound and libraries thereof
|
KR102466794B1
(en)
|
2013-12-18 |
2022-11-11 |
씨에스엘 리미티드 |
Method of treating wounds
|
CA3190821A1
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR20150092637A
(en)
|
2014-02-05 |
2015-08-13 |
삼성전자주식회사 |
p16 protein variant and composition for preventing or treating a cancer containing the same
|
KR20150092638A
(en)
|
2014-02-05 |
2015-08-13 |
삼성전자주식회사 |
p15 protein variant and composition for preventing or treating a cancer containing the same
|
KR20150097304A
(en)
|
2014-02-18 |
2015-08-26 |
삼성전자주식회사 |
Anti-EGFR/Anti-HER2 Bispecific Antibodies With Anti-EGFR DARPins
|
CA2951885C
(en)
|
2014-06-11 |
2023-07-04 |
Kathy A. Green |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
TW201625299A
(en)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
EP3626822A1
(en)
|
2014-08-15 |
2020-03-25 |
Adynxx, Inc. |
Oligonucleotide decoys for the treatment of pain
|
JP6606545B2
(en)
|
2014-09-03 |
2019-11-13 |
イミュノジェン・インコーポレーテッド |
Cytotoxic benzodiazepine derivatives
|
JP2017527562A
(en)
|
2014-09-03 |
2017-09-21 |
イミュノジェン・インコーポレーテッド |
Cytotoxic benzodiazepine derivatives
|
CN106922129B
(en)
|
2014-10-01 |
2024-02-20 |
免疫医疗有限责任公司 |
Methods of conjugating polypeptides
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
IL282922B
(en)
|
2014-11-14 |
2022-08-01 |
Hoffmann La Roche |
Antigen binding molecules comprising a tnf family ligand trimer
|
CN107405398A
(en)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
VSIG8 is identified as presumption VISTA acceptors and its to produce the purposes of VISTA/VSIG8 activators and antagonist
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
CN116869964B
(en)
|
2014-12-24 |
2024-10-18 |
耐克西缪恩有限公司 |
Nanoparticle compositions and methods for immunotherapy
|
MX2017008978A
(en)
|
2015-02-05 |
2017-10-25 |
Chugai Pharmaceutical Co Ltd |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
|
ES2953482T3
(en)
|
2015-04-02 |
2023-11-13 |
Molecular Partners Ag |
Ankyrin repeat domains designed with binding specificity for serum albumin
|
CA2978038A1
(en)
|
2015-04-17 |
2016-10-20 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
CN107921132B
(en)
|
2015-06-04 |
2021-05-07 |
圣拉斐尔医院有限公司 |
Diabetes and IGFBP3/TMEM219 axis inhibitors
|
EA201792669A1
(en)
|
2015-06-04 |
2018-06-29 |
Оспедале Сан Раффаэле Срл |
IGFBP3 AND ITS APPLICATION
|
KR101713944B1
(en)
*
|
2015-06-19 |
2017-03-09 |
한국과학기술원 |
Novel polypeptide binding with human vascular endothelial growth factor and Uses Thereof
|
MX2017016647A
(en)
|
2015-06-24 |
2019-04-25 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments.
|
BR112018001955B1
(en)
|
2015-08-03 |
2021-05-11 |
Engmab Sárl |
monoclonal antibody that binds to human b cells (bcma), pharmaceutical composition and its use
|
EP3350202A1
(en)
|
2015-09-18 |
2018-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-binding antibodies and uses thereof
|
AR106188A1
(en)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
|
CA2992863A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory tnf receptor
|
CN108137699B
(en)
|
2015-10-02 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
Bispecific antibodies specific for PD1 and TIM3
|
MY193013A
(en)
|
2015-10-07 |
2022-09-22 |
Hoffmann La Roche |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
CA3005284A1
(en)
|
2015-11-19 |
2017-05-26 |
Asclepix Therapeutics, Llc. |
Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
|
EP3383422B1
(en)
|
2015-12-02 |
2021-08-11 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
EP4421094A3
(en)
|
2016-02-05 |
2024-11-06 |
Orionis Biosciences BV |
Targeted therapeutic agents and uses thereof
|
TW202216201A
(en)
|
2016-02-12 |
2022-05-01 |
比利時商楊森製藥公司 |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
JP2019507762A
(en)
|
2016-03-07 |
2019-03-22 |
ブイアイビー ブイゼットダブリュー |
CD20 binding single domain antibody
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
CA3020848A1
(en)
|
2016-04-15 |
2017-10-19 |
Janssen Pharmaceuticals, Inc. |
Anti-human vista antibodies and use thereof
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
CN109071652B
(en)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
Antigen binding molecules comprising TNF family ligand trimers and tenascin binding modules
|
JP7105200B2
(en)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
Targeted mutant interferon-beta and its uses
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
WO2018011405A1
(en)
|
2016-07-15 |
2018-01-18 |
Universität Zürich |
Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
|
CN109661241A
(en)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
Use the method for identification plasma thromboplastin component and/or the bispecific antibody of activated clotting factor IX and Stuart factor and/or activated clotting factor X
|
JP2020501508A
(en)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
Multimers, tetramers and octamers
|
AR109680A1
(en)
|
2016-09-22 |
2019-01-09 |
Molecular Partners Ag |
RECOMBINANT PROTEINS AND THEIR USES
|
EP3515948A4
(en)
|
2016-09-23 |
2020-04-08 |
CSL Limited |
Coagulation factor binding proteins and uses thereof
|
MX2019003895A
(en)
|
2016-10-04 |
2019-10-07 |
Asclepix Therapeutics Inc |
Compounds and methods for activating tie2 signaling.
|
CN110114368B
(en)
|
2016-10-24 |
2024-08-02 |
奥睿尼斯生物科学私人有限公司 |
Targeted mutant interferon-gamma and uses thereof
|
MX2019004621A
(en)
|
2016-11-02 |
2019-11-28 |
Engmab Sarl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma.
|
KR102221364B1
(en)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
Anti-GP73 Antibody and Immunoconjugate
|
KR20230073346A
(en)
|
2016-11-28 |
2023-05-25 |
추가이 세이야쿠 가부시키가이샤 |
Ligand-binding molecule having adjustable ligand binding activity
|
IL266860B2
(en)
|
2016-11-28 |
2024-09-01 |
Chugai Pharmaceutical Co Ltd |
Polypeptide comprising antigen binding domain and carrying moiety
|
JP7125400B2
(en)
|
2016-12-19 |
2022-08-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Combination therapy with targeted 4-1BB (CD137) agonists
|
JP7247091B2
(en)
|
2016-12-20 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Combination therapy with anti-CD20/anti-CD3 bispecific antibody and 4-1BB (CD137) agonist
|
BR112019013189A2
(en)
|
2017-01-03 |
2019-12-10 |
Hoffmann La Roche |
bispecific antigen binding molecules, polynucleotide, host cell, bispecific antigen binding molecule production method, pharmaceutical composition, use, methods for inhibiting tumor cell growth in an individual and for treating cancer or an infectious disease
|
EP3576765A4
(en)
|
2017-02-06 |
2020-12-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
KR102642385B1
(en)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
Targeted chimeric proteins and uses thereof
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
WO2018160539A1
(en)
|
2017-02-28 |
2018-09-07 |
Immunogen, Inc. |
Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
WO2018178055A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
KR102687774B1
(en)
|
2017-03-31 |
2024-07-24 |
고리츠다이가쿠호징 나라켕리츠 이카다이가쿠 |
A pharmaceutical composition used for the prevention and/or treatment of blood coagulation factor IX abnormality, comprising a multispecific antigen-binding molecule that replaces the function of blood coagulation factor VIII
|
MX2019011907A
(en)
|
2017-04-04 |
2020-01-09 |
Hoffmann La Roche |
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap.
|
MX2019011910A
(en)
|
2017-04-05 |
2020-01-09 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3.
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
AR111963A1
(en)
|
2017-05-26 |
2019-09-04 |
Univ California |
METHOD AND MOLECULES
|
WO2019028427A1
(en)
|
2017-08-03 |
2019-02-07 |
Asclepix Therapeutics, Llc. |
Methods for identifying and preparing pharmaceutical agents for activating tie2 receptor
|
JP6496095B1
(en)
|
2017-09-29 |
2019-04-03 |
中外製薬株式会社 |
Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function alternative activity and pharmaceutical preparation containing the molecule as an active ingredient
|
US12059476B2
(en)
|
2017-10-10 |
2024-08-13 |
The Johns Hopkins University |
Biodegradable biomimetic particles
|
US11466073B2
(en)
|
2017-10-18 |
2022-10-11 |
Csl Limited |
Human serum albumin variants and uses thereof
|
JP2021501162A
(en)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Combination therapy with targeted OX40 agonist
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
KR20200079492A
(en)
|
2017-11-01 |
2020-07-03 |
에프. 호프만-라 로슈 아게 |
Bispecific 2+1 connector
|
CA3083346A1
(en)
|
2017-11-28 |
2019-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand-binding activity
|
TW202348632A
(en)
|
2017-11-28 |
2023-12-16 |
日商中外製藥股份有限公司 |
Polypeptide comprising antigen-binding domain and carrying part
|
CA3081770A1
(en)
|
2017-11-29 |
2019-06-06 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
TW202413360A
(en)
|
2017-12-28 |
2024-04-01 |
美商伊繆諾金公司 |
Benzodiazepine derivatives
|
JP7426724B2
(en)
|
2018-01-05 |
2024-02-02 |
エイシー イミューン ソシエテ アノニム |
Misfolded TDP-43 binding molecule
|
EP3746470A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilized immunoglobulin domains
|
CN111655730A
(en)
|
2018-01-31 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
Bispecific antibodies comprising an antigen binding site that binds to LAG3
|
EP3749295A4
(en)
|
2018-02-05 |
2022-04-27 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
US11591399B2
(en)
|
2018-02-14 |
2023-02-28 |
Abba Therapeutics Ag |
Anti-human PD-L2 antibodies
|
EP3623382A1
(en)
|
2018-09-14 |
2020-03-18 |
Universität Zürich |
Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
|
US11655293B2
(en)
|
2018-02-22 |
2023-05-23 |
Universitat Zurich |
Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
|
TWI841551B
(en)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy with targeted 4-1bb (cd137) agonists
|
MX2020009468A
(en)
|
2018-03-13 |
2020-10-22 |
Hoffmann La Roche |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies.
|
GB201804092D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Imperial Innovations Ltd |
Methods and compositions
|
WO2019180243A1
(en)
|
2018-03-22 |
2019-09-26 |
Charité-Universitätsmedizin Berlin |
Crispr associated protein reactive t cell immunity
|
AR114284A1
(en)
|
2018-04-13 |
2020-08-12 |
Hoffmann La Roche |
HER2 TARGETING ANTIGEN BINDING MOLECULES COMPOSING 4-1BBL
|
CA3097648A1
(en)
*
|
2018-04-18 |
2019-10-24 |
Altius Institute For Biomedical Sciences |
Animal pathogen-derived polypeptides and uses thereof for genetic engineering
|
WO2019229701A2
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
US20210253723A1
(en)
|
2018-06-15 |
2021-08-19 |
Universität Bern |
LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
|
JPWO2019244973A1
(en)
|
2018-06-20 |
2021-07-08 |
中外製薬株式会社 |
Methods and Compositions for Activating the Immune Response to Target Cells
|
JP2021528988A
(en)
|
2018-07-04 |
2021-10-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
New bispecific agonist 4-1BB antigen-binding molecule
|
AU2019318031A1
(en)
|
2018-08-10 |
2021-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CD137 antigen-binding molecule and utilization thereof
|
CN112955468B
(en)
|
2018-10-01 |
2024-08-09 |
豪夫迈·罗氏有限公司 |
Bispecific antigen binding molecules comprising anti-FAP clone 212
|
CN112654641A
(en)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
Bispecific antigen binding molecules with trivalent binding to CD40
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
KR20210075080A
(en)
|
2018-10-08 |
2021-06-22 |
유니베르시태트 취리히 |
HER2-binding tetrameric polypeptide
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
US20220017433A1
(en)
|
2018-11-21 |
2022-01-20 |
Universität Zürich |
Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
|
UA128001C2
(en)
|
2018-12-21 |
2024-03-06 |
Ф. Хоффманн-Ля Рош Аг |
Tumor-targeted agonistic cd28 antigen binding molecules
|
CN113286822A
(en)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
Tumor-targeting hyperactive CD28 antigen binding molecules
|
EP3677911A3
(en)
|
2019-01-03 |
2020-07-29 |
Universität Basel |
Use of non-agonist ligands for suppression of metastasis
|
EP3908274A1
(en)
|
2019-01-11 |
2021-11-17 |
Universitätsspital Basel |
Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
|
WO2020168059A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
CA3129317A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
US20220155309A1
(en)
|
2019-02-27 |
2022-05-19 |
National University Corporation Tokyo Medical And Dental University |
Fusion protein of antigen-binding protein and fluorescent protein or fluorescence-labeled tag protein
|
AU2020235455A1
(en)
|
2019-03-08 |
2021-10-28 |
Oxford Genetics Limited |
Method of selecting for antibodies
|
GB201903233D0
(en)
|
2019-03-08 |
2019-04-24 |
Oxford Genetics Ltd |
Method of selecting for antibodies
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
AU2020240310A1
(en)
|
2019-03-21 |
2021-10-07 |
Immunogen, Inc. |
Methods of preparing cell-binding agent-drug conjugates
|
TW202102506A
(en)
|
2019-03-29 |
2021-01-16 |
美商伊繆諾金公司 |
Benzodiazepine derivatives
|
EP3950938A4
(en)
|
2019-04-02 |
2023-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method of introducing target-specific foreign gene
|
US20220178926A1
(en)
|
2019-04-10 |
2022-06-09 |
Universität Zürich |
A method for determining the likelihood of a patient being responsive to cancer immunotherapy
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
CN114206444A
(en)
|
2019-04-18 |
2022-03-18 |
Ac免疫有限公司 |
Novel molecules for therapy and diagnosis
|
KR20220027828A
(en)
|
2019-04-26 |
2022-03-08 |
이뮤노젠 아이엔씨 |
camptothecin derivatives
|
KR20220010743A
(en)
|
2019-05-21 |
2022-01-26 |
노파르티스 아게 |
Trispecific binding molecules to BCMA and uses thereof
|
AU2020279974B2
(en)
|
2019-05-21 |
2024-12-19 |
Novartis Ag |
CD19 binding molecules and uses thereof
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
CN114008073A
(en)
|
2019-05-23 |
2022-02-01 |
Ac免疫有限公司 |
anti-TDP-43 binding molecules and uses thereof
|
MX2021014649A
(en)
|
2019-06-04 |
2022-01-06 |
Molecular Partners Ag |
Designed ankyrin repeat domain with improved stability.
|
WO2020245173A1
(en)
|
2019-06-04 |
2020-12-10 |
Molecular Partners Ag |
Recombinant fap binding proteins and their use
|
AR119080A1
(en)
|
2019-06-04 |
2021-11-24 |
Molecular Partners Ag |
MULTISPECIFIC PROTEINS
|
WO2020245175A1
(en)
|
2019-06-04 |
2020-12-10 |
Molecular Partners Ag |
Recombinant 4-1bb binding proteins and their use
|
JPWO2020246567A1
(en)
|
2019-06-05 |
2020-12-10 |
|
|
WO2020246563A1
(en)
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
Antibody cleavage site-binding molecule
|
US20220253669A1
(en)
|
2019-06-07 |
2022-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein
|
US20220324893A1
(en)
|
2019-06-18 |
2022-10-13 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
|
MX2021015888A
(en)
|
2019-06-26 |
2022-03-22 |
Hoffmann La Roche |
Fusion of an antibody binding cea and 4-1bbl.
|
CN114531878A
(en)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
Novel ICOS antibodies and tumor-targeted antigen-binding molecules comprising same
|
WO2021044050A1
(en)
|
2019-09-05 |
2021-03-11 |
Genome Biologics Ug |
Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
|
KR20220100611A
(en)
|
2019-11-15 |
2022-07-15 |
엔테라 에스.알.엘. |
TMEM219 antibody and therapeutic use thereof
|
WO2021099484A1
(en)
|
2019-11-20 |
2021-05-27 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Archaeal peptide recombinase – a novel peptide ligating enzyme
|
KR102416078B1
(en)
|
2019-11-20 |
2022-07-01 |
추가이 세이야쿠 가부시키가이샤 |
Antibody-containing formulations
|
WO2021099574A1
(en)
|
2019-11-21 |
2021-05-27 |
Enthera S.R.L. |
Igfbp3 antibodies and therapeutic uses thereof
|
CN115666594A
(en)
|
2019-11-29 |
2023-01-31 |
苏州诺沃泰医药科技有限公司 |
Application of CART cells in preparation of medicine for treating cancer
|
BR112022011177A2
(en)
|
2019-12-11 |
2022-09-27 |
Molecular Partners Ag |
ANCHYRIN REPETITION DOMAINS DESIGNED WITH ALTERED SURFACE RESIDUES
|
CA3161319A1
(en)
|
2019-12-11 |
2021-06-17 |
Victor LEVITSKY |
Recombinant peptide-mhc complex binding proteins and their generation and use
|
WO2021122813A1
(en)
|
2019-12-16 |
2021-06-24 |
Universität Basel |
Angiogenesis promoting agents for prevention of metastatic cancer
|
TW202144395A
(en)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
Anti-CD137 antigen-binding molecule for use in cancer treatment
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
WO2021176008A1
(en)
|
2020-03-04 |
2021-09-10 |
Cornell University |
Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
AR121706A1
(en)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
|
US20230151118A1
(en)
|
2020-04-06 |
2023-05-18 |
Universität Zürich |
Artc1 ligands for cancer treatment
|
EP4146691A1
(en)
|
2020-05-06 |
2023-03-15 |
Molecular Partners AG |
Novel ankyrin repeat binding proteins and their uses
|
EP4149959A1
(en)
|
2020-05-14 |
2023-03-22 |
Molecular Partners AG |
Multispecific proteins
|
CA3178478A1
(en)
|
2020-05-14 |
2021-11-18 |
Valerie Perrine Calabro |
Recombinant cd40 binding proteins and their use
|
IL298287A
(en)
|
2020-05-19 |
2023-01-01 |
Boehringer Ingelheim Int |
Binding molecules for the treatment of cancer
|
WO2021239844A1
(en)
|
2020-05-27 |
2021-12-02 |
Universitätsspital Basel |
Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
|
WO2021239999A1
(en)
|
2020-05-28 |
2021-12-02 |
Universität Zürich |
Il-12 pd-l1 ligand fusion protein
|
EP4168448A1
(en)
|
2020-06-23 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Agonistic cd28 antigen binding molecules targeting her2
|
CN115916830A
(en)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
anti-CD 3/anti-CD 28 bispecific antigen binding molecules
|
TW202220677A
(en)
|
2020-07-31 |
2022-06-01 |
日商中外製藥股份有限公司 |
Pharmaceutical composition comprising cell expressing chimeric receptor
|
WO2022029306A1
(en)
|
2020-08-07 |
2022-02-10 |
F. Hoffmann-La Roche Ag |
Method for producing protein compositions
|
AR123254A1
(en)
|
2020-08-14 |
2022-11-16 |
Ac Immune Sa |
HUMANIZED ANTI-TDP-43 BINDING MOLECULES AND THEIR USES
|
WO2022038193A1
(en)
|
2020-08-18 |
2022-02-24 |
Universität Zürich |
A cd25-biased anti-il-2 antibody
|
EP3957649A1
(en)
|
2020-08-18 |
2022-02-23 |
Athebio AG |
Improved n-terminal capping modules of ankyrin repeat domains
|
EP4204448A2
(en)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
EP4209227A4
(en)
|
2020-09-01 |
2024-05-29 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
|
EP4228702A1
(en)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
|
EP4229082A1
(en)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Antibodies binding to alpha-synuclein for therapy and diagnosis
|
CN112230587B
(en)
*
|
2020-10-29 |
2021-08-10 |
中国民用航空总局第二研究所 |
Instrument landing system same-frequency different-call operation monitoring system and method
|
CN116390933A
(en)
|
2020-11-06 |
2023-07-04 |
诺华股份有限公司 |
anti-CD 19 agents and B cell targeting agent combination therapies for the treatment of B cell malignancies
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
EP4244254A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Combination therapy with fap-targeted cd40 agonists
|
US20240018265A1
(en)
|
2020-12-11 |
2024-01-18 |
Friedrich Miescher Institute For Biomedical Research |
Hdac6 binding proteins and their anti-viral use
|
CA3202296A1
(en)
|
2020-12-16 |
2022-06-23 |
Sebastian Grimm |
Recombinant cd3 binding proteins and their use
|
AU2021403833A1
(en)
|
2020-12-16 |
2023-07-27 |
Molecular Partners Ag |
Novel slow-release prodrugs
|
CA3207090A1
(en)
|
2021-01-06 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
WO2022169825A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
EP4291901A1
(en)
|
2021-02-11 |
2023-12-20 |
Universität Zürich |
Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
EP4304730A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Novel darpin based cd33 engagers
|
CA3211368A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
EP4305063A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Protease cleavable prodrugs
|
US11834504B2
(en)
|
2021-03-09 |
2023-12-05 |
Molecular Partners Ag |
DARPin based multi-specific t-cell engagers
|
WO2022219185A1
(en)
|
2021-04-16 |
2022-10-20 |
Athebio Ag |
N-terminal capping modules of ankyrin repeat domains
|
WO2022244838A1
(en)
|
2021-05-19 |
2022-11-24 |
中外製薬株式会社 |
Method for predicting in vivo pharmacokinetics of molecule
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
AR126009A1
(en)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
|
BR112023026966A2
(en)
|
2021-07-02 |
2024-03-12 |
Hoffmann La Roche |
METHODS FOR TREATING AN INDIVIDUAL WITH MELANOMA, FOR ACHIEVING A CLINICAL RESPONSE, FOR TREATING AN INDIVIDUAL WITH NON-HODGKIN LYMPHOMA, FOR TREATING A POPULATION OF INDIVIDUALS WITH NON-HODGKIN LYMPHOMA, AND FOR TREATING AN INDIVIDUAL WITH METASTATIC COLORECTAL CANCER
|
AU2022323540A1
(en)
|
2021-08-05 |
2024-02-15 |
Immunos Therapeutics Ag |
Pharmaceutical compositions comprising hla fusion proteins
|
EP4380605A1
(en)
|
2021-08-05 |
2024-06-12 |
ImmunOs Therapeutics AG |
Combination medicaments comprising hla fusion proteins
|
WO2023021006A1
(en)
|
2021-08-16 |
2023-02-23 |
Universität Zürich |
Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
|
WO2023021050A1
(en)
|
2021-08-17 |
2023-02-23 |
Athebio Ag |
Variants of ankyrin repeat domains
|
EP4137508A1
(en)
|
2021-08-17 |
2023-02-22 |
Athebio AG |
Variants of ankyrin repeat domains
|
JP2024532620A
(en)
|
2021-08-30 |
2024-09-05 |
ラッセン・セラピューティクス1・インコーポレイテッド |
Anti-IL-11Rα antibody
|
WO2023036849A1
(en)
|
2021-09-07 |
2023-03-16 |
ETH Zürich |
Identifying and predicting future coronavirus variants
|
EP4163380A1
(en)
|
2021-10-08 |
2023-04-12 |
ETH Zurich |
Device and method for manipulation of extracellular vesicles
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
TW202334202A
(en)
|
2021-11-16 |
2023-09-01 |
瑞士商Ac免疫有限公司 |
Novel molecules for therapy and diagnosis
|
WO2023110942A1
(en)
|
2021-12-14 |
2023-06-22 |
Charité-Universitätsmedizin Berlin |
Prevention of impaired fracture healing
|
AU2022413461A1
(en)
|
2021-12-14 |
2024-06-06 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
CR20240246A
(en)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Agonistic ltbr antibodies and bispecific antibodies comprising them
|
WO2023117987A1
(en)
|
2021-12-21 |
2023-06-29 |
Universität Zürich |
Adenoviral vectors
|
MX2024009948A
(en)
|
2022-02-16 |
2024-08-22 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof.
|
WO2023180527A1
(en)
|
2022-03-25 |
2023-09-28 |
Universität Zürich |
Adenoviral mediated targeting of activated immune cells
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023195515A1
(en)
*
|
2022-04-06 |
2023-10-12 |
独立行政法人国立高等専門学校機構 |
Method for constructing mixed population containing nucleic acids having different sequence repeats and different numbers of repetitions
|
AU2023250038A1
(en)
|
2022-04-08 |
2024-11-14 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
EP4260907A1
(en)
|
2022-04-11 |
2023-10-18 |
Universität Zürich |
Agents for treatment of endometriosis and other benign gynecological neoplasms
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
WO2024002914A1
(en)
|
2022-06-27 |
2024-01-04 |
Charité-Universitätsmedizin Berlin |
Prediction of, and composition to improve, tendon healing
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024028278A1
(en)
|
2022-08-01 |
2024-02-08 |
Molecular Partners Ag |
Charge modified designed repeat domains and their use
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024037743A1
(en)
|
2022-08-16 |
2024-02-22 |
Athebio Ag |
Variants of ankyrin repeat domains
|
WO2023194628A2
(en)
|
2022-08-16 |
2023-10-12 |
Athebio Ag |
Variants of ankyrin repeat domains
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
WO2024044770A1
(en)
|
2022-08-26 |
2024-02-29 |
Core Biotherapeutics, Inc. |
Oligonucleotides for the treatment of breast cancer
|
WO2024047114A1
(en)
|
2022-08-31 |
2024-03-07 |
Universität Zürich |
Adenoviral-based in situ delivery of bispecific t cell engagers
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
US20240228620A1
(en)
|
2022-10-06 |
2024-07-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
WO2024074706A1
(en)
|
2022-10-07 |
2024-04-11 |
Universität Zürich |
Paracrine adenoviral delivery of biomolecules
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
WO2024118771A1
(en)
|
2022-11-30 |
2024-06-06 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
WO2024133013A1
(en)
|
2022-12-19 |
2024-06-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. |
Means and methods to target endogenous condensates
|
WO2024148241A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
WO2024148240A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
|
WO2024165671A1
(en)
|
2023-02-08 |
2024-08-15 |
Immunos Therapeutics Ag |
FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
|
WO2024179981A1
(en)
|
2023-02-27 |
2024-09-06 |
Molecular Partners Ag |
Darpins for use in reducing renal accumulation of drugs
|
WO2024184494A1
(en)
|
2023-03-08 |
2024-09-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
EP4428159A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Melanoma targeting human antibodies and therapeutic uses thereof
|
EP4428158A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Lung cancer targeting human antibodies and therapeutic uses thereof
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
WO2024208816A1
(en)
|
2023-04-03 |
2024-10-10 |
Vib Vzw |
Blood-brain barrier crossing antibodies
|